Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients

• Status: Recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

Children undergoing chemotherapy, radiation treatment and Hematopoietic Stem Cell Transplantation (HSCT) have significant difficulties achieving good oral hygiene and dental plaque control. HSCT recipients are at a significant risk for bacteremia and sepsis. Livionex® toothpaste was shown to be effective in reducing dental plaques while containing no additives found in other toothpastes that can cause increased gingival irritation. The investigators hypothesize that improved oral hygiene and better plaque control in pediatric patients receiving chemo/radiation treatment or HSCT may result in reduced oral inflammation, decreased amount of oral bacterial pathogens, and reduced risk of oral-pathogen related systemic bacterial infections. The overall goal of this prospective randomized (2:1) pilot study is to determine whether incorporation of the Livionex® toothpaste in the research regimen could reduce dental plaque.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Listerine; Sodium Fluoride

Criteria

Inclusion Criteria:

• HSCT recipient or chemo/radiation therapy patients who can cooperate with study procedures.

• Parents and patient willing to participate and sign informed consent and assent forms.

Exclusion Criteria:

• Unable to understand or participate in study procedures.

• Known allergy to edathamil or known allergy to multiple hygiene and cosmetic products.